Interestingly, Baum et al. [44] reported no hematotoxicity of 177Lu-DOTAGA-PSMA complex in patients with prostate cancer with no worsening of anemia and leukocytopenia after therapy and no grade three or four hematologic toxicity in any of the patients. Here, FOLH1 is linked to prostate cancer.